Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shara Beckwith

Nurse Practitioner, Family Flowood, MS Nurse Practitioner

NPI 1609864974 CMS profile 11156864

205A Belle Meade Pt, Flowood, MS 39232

Open in the dashboard

General payments

$12,258

703 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shara Beckwith of Flowood, MS is reported in the CMS Open Payments database as having received $12,258 across 703 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,713 140
2024 General $2,435 131
2023 General $2,076 126
2022 General $2,524 148
2021 General $2,510 158

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shara Beckwith
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Shara Beckwith were reported at $2,713. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Shara Beckwith Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,510 $124 $35–$379 $132
2022 $2,524 $141 $44–$430 $149
2023 $2,076 $154 $49–$476 $160
2024 $2,435 $165 $51–$504 $164
2025 $2,713 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,008 128 payments
  2. Novo Nordisk Inc $1,621 81 payments
  3. Pfizer Inc. $1,201 81 payments
  4. Lilly USA, LLC $1,066 77 payments
  5. AstraZeneca Pharmaceuticals LP $949 48 payments
  6. GlaxoSmithKline, LLC. $940 51 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $439 20 payments
  8. Esperion Therapeutics, Inc. $429 20 payments
  9. Amgen Inc. $426 24 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $410 24 payments
  11. Other $2,769 149 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,247 702 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $811 52 payments
  2. UBRELVY $770 45 payments
  3. VRAYLAR $769 52 payments
  4. RYBELSUS $767 50 payments
  5. NURTEC ODT $649 50 payments
  6. Wegovy $598 19 payments
  7. MOUNJARO $517 36 payments
  8. AIRSUPRA $500 20 payments
  9. QULIPTA $490 28 payments
  10. ZAVZPRET $480 39 payments
  11. Other $10,119 579 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 127 drugs

Part D claims

6,595

Median for Nurse Practitioner: 389

Drug cost

$550,393

Median for Nurse Practitioner: $21,885

Branded share of claims

19.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 93 $102,953
Jardiance Empagliflozin Brand 63 $70,666
Eliquis Apixaban Brand 91 $70,625
Farxiga Dapagliflozin Propanediol Brand 55 $63,376
Otezla Apremilast Brand 11 $49,581
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 58 $47,454
Mounjaro Tirzepatide Brand 12 $14,448
Xarelto Rivaroxaban Brand 16 $13,378
Myrbetriq Mirabegron Brand 11 $8,068
Breo Ellipta Fluticasone/Vilanterol Brand 21 $7,897

The 10 drugs with the highest cost, of 127 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$110,820

Of which drugs: $17,470

Medicare patients

229

Average age 74

Services billed

3,651

164 women, 65 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 36%
Depression 32%
Ischemic heart disease 27%
Chronic kidney disease 20%
Osteoporosis 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 34 34 $9,599
Vaccine for influenza for injection into muscle 90662 Office 71 71 $5,789
Sarscv2 vac 30mcg trs-suc im 91320 Office 11 11 $1,681
Injection, lincomycin hcl, up to 300 mg J2010 Office 14 16 $115
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 31 82 $74
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 64 $32
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 56 $19
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 48 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$241 — —
VRAYLAR
$193 — —
Wegovy
$144 — —
FARXIGA
$122 55 —
Repatha
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

703 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record